Compare Global X Defense Tech ETF (SHLD) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Defense Tech ETF vs Sanofi SA — how do they compare? Global X Defense Tech ETF trades at $59.87 (market cap $6.29B), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 15.1× Global X Defense Tech ETF's market cap, and Sanofi SA pays a 6.01% dividend while Global X Defense Tech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Global X Defense Tech ETF for 44 Days and Sanofi SA for 94 Days on average.
| SHLD | SNY | |
|---|---|---|
Market Cap | $6.29B | $95.18B |
Volume | 1,133,252 | 2,995,646 |
Sector | Sector/Thematic | Health |
52-Week High | $78.02 | $52.34 |
52-Week Low | $58.20 | $39.51 |
Typical Hold Time | 44 Days | 94 Days |
Enterprise Value | — | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SHLD, the Global X Defense Tech ETF, trades at $59.19, up 0.77% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower, while RSI levels suggest potential oversold conditions. The fund focuses on defense technology and cybersecurity, benefiting from rising global defense budgets, as highlighted by recent institutional buying and positive news flow on European rearmament efforts.
The outlook for SHLD is supported by geopolitical tailwinds and institutional accumulation, but near-term technical weakness and reliance on defense spending cycles pose risks. Investors gain exposure to innovative defense firms, yet must monitor budget approvals and market volatility.
Sanofi (SNY) trades at $40.23, showing minimal daily movement with a 0.07% gain. The stock presents mixed signals with bearish technical indicators but strong fundamental performance, including three consecutive quarterly earnings beats. Recent expansion of the immunology alliance with Regeneron through an $8 billion deal highlights strategic growth initiatives. Valuation metrics show a P/E of 22.14 and P/S of 1.77, while profitability remains solid with a 72.77% gross margin.
SNY offers steady growth potential driven by pipeline expansion and Dupixent momentum, though patent expiration risks loom. Analyst sentiment is cautiously optimistic with 44% buy ratings, but technical weakness and projected 2026 earnings decline present near-term headwinds. The stock represents a balanced opportunity for long-term investors seeking pharmaceutical exposure with manageable risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X Defense Tech ETF
SHLD tracks the Global X Defense Tech Index, targeting companies that lead the technological transformation of the defense sector. It focuses on pure-play innovators in cybersecurity, artificial intelligence, robotics, and advanced military systems, excluding traditional commercial aerospace to maintain a high level of thematic purity.
Read more on SHLD →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
